SESSION TITLE: Comorbidities of OSA Posters
SESSION TYPE: Poster Presentations
PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM
PURPOSE: The cardiovascular complications(CVC) are the important causes of mortality/morbidity in OSAS. Hypoxia, vascular endothelial dysfunction and hypercoagulability are some of the pathophysiological mechanisms. In presence of hypoxia, hematocrit increases to maintain constant delivery of oxygen to the tissue. Hyperviscosity from increased hematocrit is one of the stimuli for atherosclerotic process. Mean platelet volume(MPV) is an indicator of platelet activation and was found to be an indicator for atherosclerosis. We investigated correlation between the hematocrit and MPV levels with the severity and response of OSAS to the CPAP therapy.
METHODS: Patients were classified into four groups:. Group I:AHI<5/Hr, Group II:AHI 5-15/Hr, Group III:AHI 15-30/Hr, Group IV:AHI > 30/Hr. Demographical data, Epworth sleepiness scale(ESS), complete blood count before PSG, and all sleep recordings were retrospectively reviewed. Groups III and IVpatients underwent CPAP therapy for at least 3months. Blood samples were obtained for the comparison of Hematocrit and MPV before and after the therapy.
RESULTS: 100 patients were recruited in each group (total 400).. Mean oxygen desaturation index(ODI), duration of oxygen saturation(SpO2) below 90% and number of patients with polycythemia vera were higher and Hemoglobin levels and leukocyte counts were significantly higher in Group IV. . Hematocrit levels and MPV did not show any significant difference between the groups(p>0.05). The .Hematocrit levels significantly correlated with AHI, minSpO2, mean SpO2and duration of SpO2 below 90%. MPV significantly correlated with only mean SpO2 and the duration of SpO2 below 90%. CPAP therapy resulted in significant reductions in hematocrit and MPV levels at 3 months (p:0,03;p:0,001,respectively; N=34).
CONCLUSIONS: Hematocrit and MPV can be used to estimate the cardiovascular risks in OSAS and also to evaluate the impact of CPAP therapy. Long-term, prospective studies are needed to study the role of these inexpensive parameters in following course of CVC in OSAS.
CLINICAL IMPLICATIONS: Cardiovasuclar risk factors of OSAS and their response to therapy can be gauged in a non-invasive fashion by measuring Hematocrit and MPV.
DISCLOSURE: The following authors have nothing to disclose: Gülcan Çetin, Elif Kupeli, Serife Savas Bozbas, Füsun Öner Eyüboğlu
No Product/Research Disclosure Information